Cancer research: at the frontline
01 June, 2004 by Graeme O'NeillAustralia's biotechnology industry is tiny by comparison with its US and European counterparts, but it offers glimpses of what a future in which most cancers will be curable, or ideally, preventable, writes Graeme O'Neill.
WEHI diabetes researcher honoured
31 May, 2004 by Melissa TrudingerProf Len Harrison, of the Walter and Eliza Hall Institute, has been awarded the David Rumbough award for scientific excellence by the Juvenile Diabetes Research Foundation International for his research towards finding a cure for type 1 diabetes.
Evogenix fine-tunes Absalus antibodies in strategic alliance
28 May, 2004 by Graeme O'NeillIf you need to give your humanised monoclonal antibodies (MAbs) a gecko-like grip on their therapeutic targets, who do you call?
Does Biosilicon deliver? Uni of Pittsburgh to investigate
21 May, 2004 by Melissa TrudingerNanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
Roche achieves goals in Xeloda colon cancer study
12 May, 2004 by ReutersSwiss drug maker Roche says it has achieved its goals in a phase 111 study of its cancer drug Xeloda used to treat colon cancer.
Bionomics in technology partnership with PerkinElmer
11 May, 2004 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has announced a yin-yang collaboration with international drug-discovery, life-science research and analytical solutions company PerkinElmer.
Winter's way: why Domantis still leads in antibody technology
07 May, 2004 by Renate KrelleEngineer Greg Winter spends his days building, folding chains and working with scaffolds. He's also a librarian. But rather than cataloguing hefty manuscripts, he has viruses create each new inventory for him -- an elegant manufacturing process if ever there was one.
Prana to raise $27m from US investors
28 April, 2004 by Melissa TrudingerPrana Biotechnology (ASX:PBT) has obtained agreements to raise US$20 million (AUD$27 million) from US institutional and professional investors through the sale of 3 million ADRs at US$5 per ADR, subject to shareholder approval.
Bacterial parasite shows potential in disease control
21 April, 2004 by Lon BramThe recently completed Wolbachia pipientis gene sequence is paving the way to understanding this parasite's interaction with its insect hosts.
Optiscan breaks silence with new clinical results
19 April, 2004 by Renate KrelleMelbourne-based Optiscan Imaging (ASX:OIL) has emerged from a quiet patch with the first results from a series of clinical studies using its flexible endomicroscopes.
NHMRC gives green light to embryo research
16 April, 2004 by Renate KrelleAustralia's first licences allowing research using excess human embryos were issued today by the National Health and Medical Research Council's embryo research licensing committee.
Smile, baby -- those teeth are lifesavers
08 April, 2004 by Graeme O'NeillIn future, the tooth fairy may leave children something more than a silver coin in a glass of water, in exchange for their lost milk teeth. Researchers at the Hanson Institute in Adelaide believe pluripotent stem cells from those deciduous teeth could help sustain their owners' dental, skeletal, neural and cardiovascular health well into the autumn of their lives.
Sydney researchers uncover cancer's silent culprit
07 April, 2004 by Graeme O'NeillTwo Sydney cancer patients have made medical history this week as the first individuals to be diagnosed with cancer induced by spontaneous silencing of an otherwise normal tumour-suppressor gene.
Billionaire gives $20 million to UQ, Foundation gives $3.3 million to cancer projects
01 April, 2004 by Graeme O'NeillIf Queensland Premier Peter Beattie fulfils his ambition of appropriating Victoria’s mantle as the Biotech State, he will be indebted to itinerant Brisbane resident Chuck Feeney.
London-Brisbane vaccine research extended to kidney cancer
01 April, 2004 by Renate KrelleHaving secured patent coverage for its vaccine technology, London-based Onyvax will extend its collaboration with researchers from the Queensland University of Technology and the Princess Alexandra Hospital.
